Biosensors Collaborates with Terumo to Promote Nobori™ in Japan

       Biosensors Collaborates with Terumo to Promote Nobori™ in Japan

PR Newswire

SINGAPORE, Feb. 7, 2013

SINGAPORE, Feb.7, 2013 /PRNewswire/ -- Biosensors International Group, Ltd.
("Biosensors" or the "Company", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX:
B20), a developer, manufacturer and marketer of innovative medical devices,
has announced a collaboration with Terumo Corporation to promote the Nobori™
drug-eluting stent (DES) system at specific specialist cardiology centers in
Japan.

Nobori incorporates two elements of Biosensors-developed technology: Biolimus
A9™ (BA9™), an anti-restenotic drug developed specifically for use with
stents; and a unique abluminal biodegradable polymer coating. Following an
agreement with Terumo to manufacture, market and sell DES systems
incorporating this technology in Japan, Terumo introduced Nobori there in May
2011.

Since this time, the DES market in Japan has become increasingly competitive.
This new agreement will allow two sales forces (Terumo and Biosensors Japan)
to jointly promote Nobori, highlighting its outstanding long-term efficacy and
safety.

"We have established a strong partnership with Terumo over many years, and are
delighted by this latest agreement, which further enhances our long-term
strategic relationship," commented Jeffrey B. Jump, President of Biosensors'
Cardiovascular Business Unit. "Our two companies will continue to work closely
together to strengthen our respective technologies and provide continued
patient benefit in Japan."

The co-promotion agreement commences in April 2013, for an initial period of
three years.

About Biosensors International Group, Ltd.

Biosensors International develops, manufactures and markets innovative medical
devices for interventional cardiology and critical care procedures. We aim to
improve patients' lives through pioneering medical technology that pushes
forward the boundaries of innovation.

With the increasing use of the BioMatrix™ family of drug-eluting stents and
the recent launch of our Axxess™ self-expanding bifurcation drug-eluting
stent, we are rapidly emerging as a leader in the global coronary stent
market. The development of the BioFreedom™ drug-coated stent will further
reinforce our market position.

All three stents incorporate Biolimus A9™ (BA9™), an anti-restenotic drug
developed and patented by Biosensors specifically for use with stents. Both
the BioMatrix stent family and the Axxess stent feature a unique abluminal
biodegradable polymer coating, which fully degrades into carbon dioxide and
water after six to nine months as it releases BA9. The BioMatrix stent family
features workhorse stent platforms for a broad range of lesions, and the
Axxess stent employs a self-expanding stent platform specifically designed for
treating bifurcation lesions. BioFreedom, a completely polymer-free stent
abluminally coated with BA9, is currently undergoing clinical evaluation.

For more information, please visit www.biosensors.com.

Forward-Looking Statements

Certain statements herein include forward-looking statements within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995.
Forward-looking statements generally can be identified by the use of
forward-looking terminology, such as "may," "will," "expect," "intend,"
"estimate," "anticipate," "believe," "project" or "continue" or the negative
thereof or other similar words. All forward looking statements involve risks
and uncertainties, including, but not limited to, customer acceptance and
market share gains, competition from companies that have greater financial
resources; introduction of new products into the marketplace by competitors;
successful product development; dependence on significant customers; the
ability to recruit and retain quality employees as Biosensors grows; and
economic and political conditions globally. Actual results may differ
materially from those discussed in, or implied by, the forward-looking
statements. The forward-looking statements speak only as of the date of this
release and Biosensors assumes no duty to update them to reflect new, changing
or unanticipated events or circumstances.

Media/Investor Relations Contact

Biosensors International Group
Mr. Wong Teck Yenn
Director, Investor Relations
Tel: +65-6213-5708
Email: ty.wong@biosensors.com

SOURCE Biosensors International Group, Ltd.

Website: http://www.biosensors.com
 
Press spacebar to pause and continue. Press esc to stop.